Cargando…

Cognitive effects of Lewy body pathology in clinically unimpaired individuals

α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as isolated pathology or coexisting with Alzheimer’s disease (AD) pathology (β-amyloid (Aβ) and tau). We examined the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmqvist, Sebastian, Rossi, Marcello, Hall, Sara, Quadalti, Corinne, Mattsson-Carlgren, Niklas, Dellavalle, Sofia, Tideman, Pontus, Pereira, Joana B., Nilsson, Maria H., Mammana, Angela, Janelidze, Shorena, Baiardi, Simone, Stomrud, Erik, Parchi, Piero, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427420/ https://www.ncbi.nlm.nih.gov/pubmed/37464059 http://dx.doi.org/10.1038/s41591-023-02450-0

Ejemplares similares

Clinical effects of Lewy body pathology in cognitively impaired individuals
por: Quadalti, Corinne, et al.
Publicado: (2023)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
por: Pereira, Joana B., et al.
Publicado: (2023)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
por: Arvidsson, Ida, et al.
Publicado: (2023)

The implications of different approaches to define AT(N) in Alzheimer disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
por: Pereira, Joana B, et al.
Publicado: (2021)

RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease
por: Mammana, Angela, et al.
Publicado: (2021)

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
por: Gertje, Eske Christiane, et al.
Publicado: (2023)

Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
por: Cicognola, Claudia, et al.
Publicado: (2023)

The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults
por: Insel, Philip S., et al.
Publicado: (2020)

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes
por: Ygland Rödström, Emil, et al.
Publicado: (2022)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
por: Johansson, Maurits, et al.
Publicado: (2021)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly
por: Hahn, Andreas, et al.
Publicado: (2019)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People
por: Nilsson, Maria H, et al.
Publicado: (2020)

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
por: Kumar, Atul, et al.
Publicado: (2021)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Towards a unified protocol for handling of CSF before β-amyloid measurements
por: Janelidze, Shorena, et al.
Publicado: (2019)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2021)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8slm00s4qqg68g5ffn7slt8qbq